Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArdelyxARDX -1.51%66 3-Year EBITDA Growth Rate is 32.00% as of Jun. 2026, which is 264% above its 10-year median of 8.80. GuruFocus rates ARDX with a GF Score™ of 66/100 and a GF Value™ of $8.70 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,131 Biotechnology companies, Ardelyx ranks better than 70.03% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 32.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 43.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 26.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ardelyx was 63.40% per year. The lowest was -153.50% per year. And the median was 8.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ardelyx 3-Year EBITDA Growth Rate Related Terms
ARDX vs IMTX, TRAX, AVLN: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Ardelyx's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ardelyx's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 32.00% mean?
Ardelyx (ARDX) has a 3-Year EBITDA Growth Rate of 32.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ardelyx and its competitors. This is 264% above median its historical median of 8.80. According to the industry distribution chart, Ardelyx ranks #339 out of 1131 companies in the Biotechnology industry, placing it in the top 30%.
Is Ardelyx's 3-Year EBITDA Growth Rate too high?
Ardelyx's current 3-Year EBITDA Growth Rate of 32.00% is 264% above median its 10-year median of 8.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Ardelyx's value of 32.00% is 114.8% above this industry median. Based on the distribution chart, Ardelyx ranks #339 out of 1131 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ardelyx has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's 3-Year EBITDA Growth Rate compare to IMTX and TRAX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #339 out of 1131 companies for 3-Year EBITDA Growth Rate. This puts Ardelyx in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Ardelyx's value of 32.00% is 114.8% above this benchmark. While the company's 10-year median is 8.80 vs. the industry median of 14.90, Ardelyx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ardelyx's current 3-Year EBITDA Growth Rate of 32.00% is 114.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ardelyx and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ardelyx's current 3-Year EBITDA Growth Rate is 32.00%, which is 264% above median its own 10-year median of 8.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is $8.70, compared to a current price of $3.90 — trading 55.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 32.00%, which is 264% above median its 10-year median of 8.80 and 114.8% above the Biotechnology industry median of 14.90. Ardelyx's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ardelyx (ARDX), the current 3-Year EBITDA Growth Rate is 32.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ardelyx (ARDX) Overvalued in 2026?
Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued.
The current stock price of $3.90 is trading 55.2% below its estimated GF Value™ of $8.70.
GuruFocus considers Ardelyx to be Possible Value Trap.
Key valuation signals for ARDX:
3-Year EBITDA Growth Rate: 32.00% (264% above median its 10-year median of 8.80)
GF Value™: $8.70 vs. price of $3.90 (55.2% below fair value)
Industry Position: 114.8% above the Biotechnology median (#339 of 1131)
No single metric tells the full story. See the ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
66GF Score
Get the complete analysis for ARDX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARDX has been successfully added to your 
